CROs offering Discovery Research with Vaccine
8 published
8 published CROs match Discovery Research and Vaccine.
Locations in this set include United States, China, India, 30 countries, 30+ countries, and Australia.
Capabilities that show up most often in this set: Translational Research, Biomarker Assays, Bioanalysis, GLP Toxicology, and In Vivo PK / PD Studies.
Matching companies
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
CertaraCertara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
KCAS BioLeading bioanalytical CRO with 45+ years of experience, supporting 315+ approved drugs through bioanalysis, biomarker, immunogenicity, flow cytometry, and clinical kitting services across US, EU, and Australia facilities.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
QIAGEN Discovery SciencesQIAGEN Discovery Sciences delivers genomics, bioinformatics, and molecular analysis solutions spanning research discovery through clinical diagnostics, with expertise in nucleic acid extraction, digital PCR, NGS workflows, and omics data interpretation.
Sussex Research Laboratories Inc.Global leader in carbohydrate and glycan synthesis, offering custom synthesis, CRO, and CDMO services for drug discovery and development. Specializes in GalNAc targeting ligands, glycopeptides, and glycoconjugates with over 25 years of expertise.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/discovery-research/vaccine.md